Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CPT2 | P23786 | 2/20 | 0.47 |
| ▸ | CPT1A | P50416 | 2/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684836 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3684830 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3686204 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3682504 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3687140 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3682503 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3686202 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3677874 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3677878 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 | |
| SCHEMBL3684467 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CA12 1697/4885CA1 1983/4885CA2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.